ESC 365 - P2Y12 inhibitor choice in non-ST elevation acute coronary syndromes: prasugrel, ticagrelor or clopidogrel?

ESC Premium Access

P2Y12 inhibitor choice in non-ST elevation acute coronary syndromes: prasugrel, ticagrelor or clopidogrel?

Session: Hot Topics in Non-ST Elevation Acute Coronary Syndromes

Topic: Treatment

Speaker: Doctor A. Salvati (Buenos Aires, AR)

Event: ESC Congress 2020

Congress Presentation

About the speaker

Doctor Ana Maria Salvati

Clinica Modelo de Moron, Buenos Aires (Argentina)

1 presentation

0 follower

1 more presentation in this session

Shorter double antiplatelet treatment in acute coronary syndromes: for whom?

Speaker: Professor M. Valgimigli (Lugano, CH)

Access the full session

Hot Topics in Non-ST Elevation Acute Coronary Syndromes

Speakers: Doctor A. Salvati, Professor M. Valgimigli

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

Related content

ESC Premium Access

Triglycerides: the underestimated player.

27 August 2021

ESC Premium Access

Nationwide trends in stroke and atrial fibrillation in patients with incident type 2 diabetes

27 August 2021

ESC Premium Access

Benefits of SGLT2-1/2 Inhibition on Heart Failure, Ischemic, and Kidney Endpoints

27 August 2021

ESC 365 is supported by